Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Campos

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Gynecologic Oncology|September 10, 2002
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapyMichael V Seiden, Kenneth D Swenerton, Ursula Matulonis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 13, 2008
Cervical cancer screeningEdward E Partridge, Nadeem Abu-Rustum, Susan Campos, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Gynecologic Oncology|September 10, 2002
A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapyMichael V Seiden, Kenneth D Swenerton, Ursula Matulonis, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 13, 2008
Cervical cancer screeningEdward E Partridge, Nadeem Abu-Rustum, Susan Campos, et al.
Pageof 1